GlaxoSmithKline plc Q3 2025 Earnings Recap

GSK delivered robust Q3 results, with total sales rising 8% and core earnings per share increasing 14% to 55p, prompting an upward revision of its full-year guidance.

Key Takeaways

• Specialty medicines revenue surged 16% driven by strong performances in RI&I, oncology, and HIV.
• GSK secured four FDA approvals in 2025, bolstering its late-stage pipeline.
• Cash generation remains strong at £6.3 billion YTD, supporting investments and a quarterly dividend of 16p.
• The strengthened balance sheet and ongoing operational improvements have allowed for an upgrade in long-term sales outlook to over £40 billion by 2031.
• Significant R&D investment of $30 billion planned over the next five years, including construction of a new biologics facility in Pennsylvania.